Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A for Prevention of Relapse in Generalized Anxiety Disorder
NCT00397098Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing SR58611A with Placebo (2 arms). Primary endpoint: Time to relapse of anxious symptoms. Started Nov 2006; status: terminated.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00397098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397098.